These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16610790)

  • 1. Optimal charges in lead progression: a structure-based neuraminidase case study.
    Armstrong KA; Tidor B; Cheng AC
    J Med Chem; 2006 Apr; 49(8):2470-7. PubMed ID: 16610790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charge optimization of the interface between protein kinases and their ligands.
    Sims PA; Wong CF; McCammon JA
    J Comput Chem; 2004 Aug; 25(11):1416-29. PubMed ID: 15185335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-ligand binding affinity predictions by implicit solvent simulations: a tool for lead optimization?
    Michel J; Verdonk ML; Essex JW
    J Med Chem; 2006 Dec; 49(25):7427-39. PubMed ID: 17149872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.
    Stoll V; Stewart KD; Maring CJ; Muchmore S; Giranda V; Gu YG; Wang G; Chen Y; Sun M; Zhao C; Kennedy AL; Madigan DL; Xu Y; Saldivar A; Kati W; Laver G; Sowin T; Sham HL; Greer J; Kempf D
    Biochemistry; 2003 Jan; 42(3):718-27. PubMed ID: 12534284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategy for theoretical binding constant, Ki, calculations for neuraminidase aromatic inhibitors designed on the basis of the active site structure of influenza virus neuraminidase.
    Jedrzejas MJ; Singh S; Brouillette WJ; Air GM; Luo M
    Proteins; 1995 Oct; 23(2):264-77. PubMed ID: 8592707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling of human sialidase enzymes NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: hints for the design of selective NEU3 inhibitors.
    Magesh S; Suzuki T; Miyagi T; Ishida H; Kiso M
    J Mol Graph Model; 2006 Oct; 25(2):196-207. PubMed ID: 16427342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations.
    Masukawa KM; Kollman PA; Kuntz ID
    J Med Chem; 2003 Dec; 46(26):5628-37. PubMed ID: 14667217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
    Mitrasinovic PM
    Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions.
    Abu Hammad AM; Afifi FU; Taha MO
    J Mol Graph Model; 2007 Sep; 26(2):443-56. PubMed ID: 17360207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
    D'Ursi P; Chiappori F; Merelli I; Cozzi P; Rovida E; Milanesi L
    Biochem Biophys Res Commun; 2009 Jun; 383(4):445-9. PubMed ID: 19371724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of different electrostatic potentials on docking accuracy: a case study using DOCK5.4.
    Tsai KC; Wang SH; Hsiao NW; Li M; Wang B
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3509-12. PubMed ID: 18502122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coupled atomic charge selectivity for optimal ligand-charge distributions at protein binding sites.
    Bhat S; Sulea T; Purisima EO
    J Comput Chem; 2006 Dec; 27(16):1899-907. PubMed ID: 16988958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dynamics and free energy analysis of neuraminidase-ligand interactions.
    Bonnet P; Bryce RA
    Protein Sci; 2004 Apr; 13(4):946-57. PubMed ID: 15044728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening.
    Steindl T; Langer T
    J Chem Inf Comput Sci; 2004; 44(5):1849-56. PubMed ID: 15446845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the role of electrostatic interactions in the design of protein-protein interfaces.
    Sheinerman FB; Honig B
    J Mol Biol; 2002 Apr; 318(1):161-77. PubMed ID: 12054776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scoring binding affinity of multiple ligands using implicit solvent and a single molecular dynamics trajectory: application to influenza neuraminidase.
    Bonnet P; Bryce RA
    J Mol Graph Model; 2005 Oct; 24(2):147-56. PubMed ID: 16098779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.
    Maring CJ; Stoll VS; Zhao C; Sun M; Krueger AC; Stewart KD; Madigan DL; Kati WM; Xu Y; Carrick RJ; Montgomery DA; Kempf-Grote A; Marsh KC; Molla A; Steffy KR; Sham HL; Laver WG; Gu YG; Kempf DJ; Kohlbrenner WE
    J Med Chem; 2005 Jun; 48(12):3980-90. PubMed ID: 15943472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
    Abu Hammad AM; Taha MO
    J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
    Zhou Z; Bates M; Madura JD
    Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.